Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Schuth Alexander O. | COFO and Secretary | May 15 | Option Exercise | 5.28 | 10,000 | 52,800 | 538,691 | May 17 04:56 PM | Schuth Alexander O. | COFO and Secretary | May 15 | Sale | 28.60 | 10,000 | 286,044 | 528,691 | May 17 04:56 PM | Watts Ryan J. | President and CEO | Apr 21 | Option Exercise | 0.68 | 24,800 | 16,864 | 2,264,713 | Apr 24 07:10 PM | Watts Ryan J. | President and CEO | Apr 21 | Sale | 25.15 | 24,800 | 623,720 | 2,239,913 | Apr 24 07:10 PM | Watts Ryan J. | President and CEO | Apr 20 | Option Exercise | 0.68 | 200 | 136 | 2,240,113 | Apr 24 07:10 PM | Watts Ryan J. | President and CEO | Apr 20 | Sale | 25.00 | 200 | 5,000 | 2,239,913 | Apr 24 07:10 PM | Schuth Alexander O. | COFO and Secretary | Apr 13 | Option Exercise | 5.28 | 4,898 | 25,861 | 533,589 | Apr 14 06:27 PM | Schuth Alexander O. | COFO and Secretary | Apr 13 | Sale | 25.04 | 4,898 | 122,646 | 528,691 | Apr 14 06:27 PM | Schuth Alexander O. | COFO and Secretary | Apr 12 | Option Exercise | 5.28 | 5,102 | 26,939 | 533,793 | Apr 14 06:27 PM | Schuth Alexander O. | COFO and Secretary | Apr 12 | Sale | 25.04 | 5,102 | 127,754 | 528,691 | Apr 14 06:27 PM | Ho Carole | Chief Medical Officer | Feb 15 | Sale | 29.40 | 1,476 | 43,394 | 182,809 | Feb 17 04:20 PM | Watts Ryan J. | President and CEO | Feb 13 | Option Exercise | 0.68 | 25,000 | 17,000 | 2,264,913 | Feb 15 07:01 PM | Schuth Alexander O. | COFO and Secretary | Feb 13 | Option Exercise | 0.68 | 25,000 | 17,000 | 524,902 | Feb 15 07:01 PM | Watts Ryan J. | President and CEO | Feb 13 | Sale | 30.08 | 33,815 | 1,017,243 | 2,239,913 | Feb 15 07:01 PM | Schuth Alexander O. | COFO and Secretary | Feb 13 | Sale | 30.09 | 3,497 | 105,225 | 528,691 | Feb 15 07:01 PM | Ho Carole | Chief Medical Officer | Feb 13 | Sale | 30.10 | 2,548 | 76,695 | 184,285 | Feb 14 07:06 PM | Krognes Steve E. | Director | Feb 13 | Sale | 30.10 | 2,119 | 63,782 | 143,002 | Feb 15 07:02 PM | Watts Ryan J. | President and CEO | Feb 10 | Option Exercise | 0.68 | 25,000 | 17,000 | 2,254,031 | Feb 13 07:14 PM | Watts Ryan J. | President and CEO | Feb 10 | Sale | 29.10 | 25,000 | 727,500 | 2,229,031 | Feb 13 07:14 PM | Ho Carole | Chief Medical Officer | Feb 10 | Sale | 29.80 | 818 | 24,376 | 179,365 | Feb 14 07:06 PM | Watts Ryan J. | President and CEO | Feb 09 | Sale | 30.59 | 3,433 | 105,015 | 2,229,031 | Feb 13 07:14 PM | Schuth Alexander O. | COFO and Secretary | Feb 08 | Sale | 30.89 | 1,521 | 46,984 | 499,902 | Feb 10 06:11 PM | Ho Carole | Chief Medical Officer | Feb 08 | Sale | 30.88 | 1,521 | 46,968 | 180,183 | Feb 10 06:12 PM | Krognes Steve E. | Director | Feb 08 | Sale | 30.88 | 1,377 | 42,522 | 145,121 | Feb 10 06:10 PM | Schuth Alexander O. | COFO and Secretary | Jan 17 | Option Exercise | 5.28 | 10,000 | 52,800 | 507,173 | Jan 19 05:09 PM | Schuth Alexander O. | COFO and Secretary | Jan 17 | Sale | 29.53 | 10,000 | 295,339 | 497,173 | Jan 19 05:09 PM | Ho Carole | Chief Medical Officer | Jan 09 | Sale | 28.48 | 1,459 | 41,552 | 177,454 | Jan 10 04:51 PM | Ho Carole | Chief Medical Officer | Jan 06 | Sale | 28.67 | 1,451 | 41,600 | 178,913 | Jan 09 09:43 PM | Watts Ryan J. | President and CEO | Jan 05 | Sale | 28.44 | 4,800 | 136,512 | 2,223,664 | Jan 09 09:41 PM | Krognes Steve E. | Director | Jan 05 | Sale | 28.44 | 2,970 | 84,467 | 146,498 | Jan 09 09:42 PM | Ho Carole | Chief Medical Officer | Jan 05 | Sale | 28.44 | 2,636 | 74,968 | 180,364 | Jan 09 09:43 PM | Schuth Alexander O. | COFO and Secretary | Jan 05 | Sale | 28.44 | 2,636 | 74,968 | 497,173 | Jan 09 09:41 PM | Watts Ryan J. | President and CEO | Jan 04 | Sale | 28.73 | 5,029 | 144,483 | 2,213,464 | Jan 05 09:07 PM | Schuth Alexander O. | COFO and Secretary | Jan 04 | Sale | 28.70 | 2,912 | 83,574 | 149,828 | Jan 05 09:07 PM | Ho Carole | Chief Medical Officer | Jan 04 | Sale | 28.69 | 2,913 | 83,574 | 175,500 | Jan 05 09:08 PM | Tessier-Lavigne Marc | Director | Nov 23 | Sale | 30.48 | 20,000 | 609,600 | 1,870,356 | Nov 28 07:30 PM | Tessier-Lavigne Marc | Director | Nov 02 | Sale | 30.33 | 11,252 | 341,273 | 1,890,356 | Nov 03 05:37 PM | Tessier-Lavigne Marc | Director | Nov 01 | Sale | 30.20 | 8,748 | 264,190 | 1,901,608 | Nov 03 05:37 PM | Schuth Alexander O. | COFO and Secretary | Oct 07 | Option Exercise | 0.68 | 20,000 | 13,600 | 487,471 | Oct 12 04:05 PM | Tessier-Lavigne Marc | Director | Sep 28 | Sale | 30.82 | 20,000 | 616,304 | 1,910,356 | Sep 30 04:50 PM | Tessier-Lavigne Marc | Director | Aug 23 | Sale | 31.61 | 20,000 | 632,282 | 1,930,356 | Aug 25 06:11 PM | Ho Carole | Chief Medical Officer | Aug 23 | Sale | 31.98 | 2,424 | 77,520 | 170,663 | Aug 25 06:10 PM | Schuth Alexander O. | COFO and Secretary | Aug 19 | Sale | 33.22 | 2,576 | 85,575 | 467,471 | Aug 23 04:46 PM | Ho Carole | Chief Medical Officer | Aug 19 | Sale | 33.22 | 2,576 | 85,575 | 173,087 | Aug 23 04:45 PM | Watts Ryan J. | President and CEO | Aug 19 | Sale | 33.22 | 2,404 | 79,861 | 2,202,993 | Aug 23 04:48 PM | Krognes Steve E. | Director | Aug 19 | Sale | 33.22 | 2,253 | 74,845 | 149,468 | Aug 23 04:47 PM | Tessier-Lavigne Marc | Director | Jul 25 | Sale | 35.61 | 20,000 | 712,110 | 1,950,356 | Jul 27 06:49 PM | Krognes Steve E. | Director | Jul 19 | Option Exercise | 0.68 | 62,500 | 42,500 | 151,721 | Jul 21 07:36 PM |
|